FDA Approved: LEDIPASVIR AND SOFOSBUVIR — Supplemental Application (Asegua Therapeutics LLC)

View source ↗

Summary

FDA approved a supplemental NDA for Ledipasvir and Sofosbuvir from Asegua Therapeutics LLC, approving a generic combination product for hepatitis C treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ledipasvir and Sofosbuvir (Ledipasvir and Sofosbuvir)

Snippet

SUPPL AP for LEDIPASVIR AND SOFOSBUVIR (LEDIPASVIR AND SOFOSBUVIR)